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A systematic review was conducted of epidemiological studies focusing on the association between 
smokeless tobacco (SLT) use and coronary heart disease (CHD) in order to summarize the evidence 
and to identify scope for further study in South Asian countries. PubMed and ISI Web of Science 
databases were searched to find epidemiological studies (cohort, case-control and cross-sectional) 
published until 27 October, 2011. The search revealed 592 relevant references, from which 18 
epidemiological studies were selected. Among the 18 studies, 11 studies were conducted in Sweden, 4 
in the USA, 1 in India, 1 in Bangladesh, and 1 study was multi-centric involving 52 countries. Twelve 
studies included only men and six studies included both sexes. Three studies used South Asian SLT 
products. Nine studies found no statistically significant positive association between SLT use and CHD, 
while nine studies did find a positive association. Results of these studies differed according to age, 
gender, and SLT constituents. Currently published research does not provide conclusive evidence 
regarding the association between SLT use and CHD. SLT products and usage pattern in South Asia 
differ from those in Western settings, and cannot be extrapolated immediately to South Asian settings. 
 
Key words: Smokeless tobacco, chewing tobacco, oral tobacco, coronary heart disease, cardiovascular 
diseases. 
 
 
INTRODUCTION 
 
Smokeless tobacco (SLT) includes “a large variety of 
commercially or non-commercially available products and 
mixtures that contain tobacco as the principal constituent 
and are used either orally or nasally without combustion” 
(International Agency for Research on Cancer, 2007). 
The oral forms of SLT are chewed or kept between cheek 
and gum, whereas nasal forms are inhaled. SLT products 
are used alone or as ingredients in other products,  some  
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Abbreviations: CHD, coronary heart disease; CVD, 
cardiovascular diseases; SLT, smokeless tobacco. 
in the raw form and others as commercial products. SLT, 
the use of which has spread to many countries in recent 
years, has been used by the South American and South 
Asian people for thousands of years (US National Cancer 
Institute, 2002). SLT is commonly used in many countries 
of Europe, America, Africa, and in Asian countries such 
as India, Pakistan and Bangladesh (International Agency 
for Research on Cancer, 2007). The use of SLT varies by 
age, sex, ethnicity and socioeconomic status, both within 
and among countries (Boffetta et al., 2008). 
Coronary heart disease (CHD), which accounted for 
more than seven million deaths in 2004, is the leading 
cause of mortality worldwide (World Health Organization, 
2008). Among the risk factors of CHD, tobacco use is the 
second most important following hypertension (World 
Health   Organization,  2009).  According   to   the   World  
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Health Organization (WHO), tobacco is the most 
important preventable cause of death (World Health 
Organization, 2008). It is projected that the number of 
tobacco-attributable deaths will increase from 5.4 million 
in 2004 to 8.3 million in 2030 (World Health Organization, 
2008). Of these 5.4 million deaths, 0.9 million deaths 
were due to CHD caused by tobacco use in 2004 (World 
Health Organization, 2008). 
The association between smoking and CHD is well 
established, but the association between SLT use and 
CHD is in dispute (Piano et al., 2010; Lee, 2011). Most 
reviews of the epidemiological studies on SLT use and 
CHD have included Swedish studies only (Asplund, 2003; 
Critchley et al., 2003; Critchley et al., 2004; Gupta et al., 
2004), or both Swedish and US studies (Lee, 2007; 
Boffetta et al., 2009). Meta-analysis of these Western 
studies (Lee, 2007; Boffetta and Straif, 2009) did not find 
a significant positive association between current SLT 
use and CHD. The result was similar when Swedish and 
US studies were analyzed separately, although there was 
a significant positive association when only fatal CHD 
was considered (RR 1.17, 95% CI 1.09 to 1.25) (Boffetta 
and Straif, 2009). On the other hand, a review published 
in 2010 (Zhang et al., 2010), which included eight Asian 
studies but excluded Western studies, found a significant 
association between use of chewed products and CHD 
(RR 1.27, 95CI 1.02 to 1.52); chewed products included 
betel chewing with or without tobacco. However, when 
analyses were confined to three South Asian studies, the 
association was not significant statistically (RR 1.64, 95% 
CI 0.60 to 2.68) (Zhang et al., 2010).  
In South Asian countries, betel-quid chewing is one of 
the long standing cultural traditions of the people. Betel-
quid includes betel leaf, areca nut and slaked lime; SLT 
products are commonly used as an ingredient with betel-
quid chewing (Gupta et al., 2003, 2004). Over 250 million 
people, constituting 17% of the total population of the 
WHO South-East Asia region, use SLT products 
(International Agency for Research on Cancer, 2007). In 
south Asian countries, while smoking by women is not 
supported by traditional values, SLT use does not have any 
such stigma (Gupta and Ray, 2003). Therefore, prevalence 
of SLT use is high among women in this region (Centers 
for Disease Control and Prevention) unlike the Western 
settings. On the other hand, prevalence of CHD is the 
highest among South Asian people compared to other 
parts of the world, not only due to behavioural factors but 
also for the genetic predisposition (Nishtar, 2002). 
Although studies from Taiwan (Guh et al., 2007; Lin et al., 
2008; Yen et al., 2008) reported a significant positive 
association between betel-quid chewing and CHD, 
studies exploring the association between SLT use and 
CHD within South Asian context are very limited. We only 
considered CHD for our review, as CHD is the most 
important preventable cardiovascular diseases (CVD) 
(Nishtar, 2002). Furthermore, South Asian people have 
an early onset of CHD and die prematurely due to CHD 
compared   to   other   Caucasians  (Silbiger et al., 2011). 
 
 
 
 
Our aim was to review the existing epidemiological 
studies regarding the association between SLT use and 
CHD in order to summarise the currently available 
evidence, consider strengths and limitations of previous 
studies and through this process explore the rational for 
conducting further studies, particularly in South Asia. 
 
 
METHODS 
 
Muhammad Aziz Rahman, Nicola Spurrier and Mohammad Afzal 
Mahmood discussed and agreed on the search terms required and 
the approach to the literature search. Muhammad Aziz Rahman 
undertook the literature search and reviewed all publications 
systematically using set criteria. Muhammad Aziz Rahman 
reviewed the search results three times before confirming the 
results. We followed the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) guidelines (Moher et al., 
2009). We searched the literature in the manner recommended by 
The Cochrane Collaboration (Higgins and Green, 2011) and Bown 
et al. (2010). We selected SLT use as the main exposure variable 
and CHD as the main outcome variable for this review. Our focus 
was to identify the studies reporting CHD as the outcome, not the 
risk factors for CHD (blood pressure, body mass index, and lipid 
profile). PubMed and ISI Web of Science were selected as the 
primary databases for this review, as others have done (Lee, 2007; 
Boffetta and Straif, 2009; Zhang et al., 2010). Inclusion criteria were 
English language and data published until 27 October, 2011. 
Searching PubMed for literature on SLT only, 4500 references were 
obtained. Searching PubMed on CHD only, 1295852 references 
were obtained. Combining SLT and CHD, 231 references were 
obtained.  
The search terms used to obtain references for SLT and CHD 
were: “Tobacco, smokeless [mh], Smokeless tobacco*[tiab], 
chewing tobacco*[tiab], Chewable tobacco*[tiab], Oral 
tobacco*[tiab], tobacco chewing*[tiab], Tobacco chewer*[tiab], Spit 
tobacco*[tiab], Snuff*[tiab], Snus*[tiab], Betel quid*[tiab], Betel 
chewing*[tiab], Betel nut*[tiab], or Betel leaf*[tiab] and Ischemic 
heart disease*[tiab], Ischaemic heart disease*[tiab], cardiovascular 
diseases*[mh], cardiovascular disease*[tiab], Cardiovascular 
risk*[tiab], Myocardial ischemia*[tiab], or Myocardial 
ischaemia*[tiab], or Acute Coronary Syndrome*[tiab], Angina 
Pectoris*[tiab], Unstable angina*[tiab], Microvascular Angina*[tiab], 
Coronary Disease*[tiab],  Coronary heart disease*[tiab], Coronary 
Aneurysm*[tiab], Coronary Artery Disease*[tiab], Coronary 
Occlusion*[tiab], Coronary Stenosis*[tiab], Coronary 
Thrombos*[tiab], Coronary Vasospasm*[tiab], Myocardial 
Infarct*[tiab], Myocardial Stunning*[tiab], cardiogenic shock*[tiab], 
Myocardial Reperfusion Injur*[tiab] or Heart disease*[tiab]”.  
The same search strategy and terms were then used for ISI Web 
of Knowledge. The initial search yielded 6869 references on SLT 
and 523337 references on CHD. When search terms were 
combined for SLT and CHD, 334 references were obtained.   
Figures 1 and 2 summarises the search strategy used and the 
number of articles obtained at each step. Among the 565 
references retrieved from both PubMed and ISI Web of Science, 
105 duplicates were excluded. Titles and abstracts were reviewed, 
and references which did not clearly relate to tobacco and/or heart 
disease were excluded (n=118), resulting in 342 references.  
Then, searches were extended to EMBASE and The Cochrane 
Library, which are considered the richest databases along with 
PubMed (The Cochrane Collaboration, 2006; Bown and Sutton, 
2010). Additional searches were conducted using Scopus, Google 
Scholar and WHO publications. To ensure all studies from Asian 
countries were included, further search was conducted using the 
following terms: Asia*[mh], India*[tiab], Pakistan*[tiab], 
Bangladesh*[tiab], or South Asia*[tiab]. In addition, local  databases  
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Figure 1. Search strategy for selection of epidemiological studies exploring the association between coronary heart 
disease and smokeless tobacco use. 
 
 
 
of Bangladesh, India and Pakistan were also reviewed. These 
included the WHO Bangladesh publications, Bangladesh Journals 
Online, ICDDRB publications, Indian Journal of Public Health, 
Journal of the Associations of Physicians of India (JAPI) and 
PakMediNet. Finally, the reference lists of all SLT-related articles 
were hand searched. All of these additional searches identified 250 
more references. A total of 592 relevant references were obtained. 
References concerned with tobacco-related issues in general or 
different smoking-related issues such as harmful effects of smoking, 
smoking cessation interventions and nicotine replacement therapies 
were excluded (n=196). Although ‘betel-quid’, ‘betel-nut’ or ‘areca-
nut’ chewing does not contain tobacco (Wen et al., 2005; Guh et al., 
2007; Lan et al., 2007; Lin et al., 2008; Yen et al., 2008), we 
included them initially as SLT products in the search terms to allow 
the widest coverage of the available literature. When it was clear 
that the study did not include other SLT products, the study was 
excluded from the review (n=18). Then, SLT-related issues in 
general such as prevalence estimation, molecular/genetic change 
analyses, constituent analyses, impact of SLT use on smoking, 
comparing health effects of smoking and SLT use, SLT cessation 
strategies, perception analyses, harm reduction potential and policy 
were also excluded (n=192). In addition, cardiovascular disease-
related issues such as prevalence estimation, risk factor analysis 
and prevention strategies were also excluded (n=69).  
The remaining references (n=117) were reviewed and references 
relating to SLT and health effects other than CHD (n=69), SLT and 
risk factors for cardiovascular diseases (CVD) such as 
hypertension, body mass index, and lipid profile (n=10), letters and 
conference proceedings related to SLT and CHD (n=6), and 
reviews on SLT and CHD (n=14) were excluded. Eighteen studies 
remained, which explored the association between SLT use and 
CHD. For our reviews, we searched the results specific for CHD, 
but if any study reported only CVD in general we also included that 
result. For the association between SLT use and CHD, we tried to 
find out the association among never-smoker population in that 
study. 
 
 
RESULTS 
 
Characteristics of the included studies 
 
Among the 18 studies, 10 were cohort studies (Bolinder 
et al., 1994; Accortt et al., 2002; Gupta et al., 2005; 
Henley et al., 2005; Johansson et al., 2005; Haglund et 
al., 2007; Hergens  et  al.,  2007;  Hansson  et  al.,  2009;  
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Figure 2. Characteristics of the selected epidemiological studies exploring the association between coronary 
heart disease and smokeless tobacco use.  
 
 
 
Janzon et al., 2009; Yatsuya et al., 2010), six were case-
control studies (Huhtasaari et al., 1992, 1999; Hergens et 
al., 2005; Teo et al., 2006; Wennberg et al., 2007; 
Rahman and Zaman, 2008) and two were cross-sectional 
studies (Bolinder et al., 1992; Nasir et al., 2010). Studies 
were conducted mainly in Sweden (n=11) and the 
Swedish studies concentrated on the use of snuff (n=8). 
Three studies used South Asian SLT products, but only 
two studies (Gupta et al., 2005; Rahman and Zaman, 
2008) were conducted in South Asian regions (India and 
Bangladesh). The third study was global, INTERHEART 
study (Teo et al., 2006), which included SLT products 
from 52 countries including few South Asian countries. 
Men only were included in the majority of the studies 
(n=12), either during recruitment of the study participants 
or during analyses of the findings; as report of SLT use 
was much lower among women. The Swedish studies 
concentrated on the use of snuff (n=8), and only two 
studies were concerned with South Asian SLT products 
exclusively. Four studies reported outcome as fatal CHD, 
three reported outcome as non-fatal CHD, and ten 
studies reported outcome as both fatal and non-fatal 
CHD. 
Nine studies reported a statistically significant positive 
association between SLT use and CHD  (Bolinder  et  al., 
1992, 1994; Gupta et al., 2005; Henley et al., 2005; Teo 
et al., 2006; Hergens et al., 2007; Rahman and Zaman, 
2008; Nasir et al., 2010; Yatsuya and Folsom, 2010), and 
nine studies failed to find a significant association 
(Huhtasaari et al., 1992, 1999; Accortt et al., 2002; 
Hergens et al., 2005; Johansson et al., 2005; Haglund et 
al., 2007; Wennberg et al., 2007; Hansson et al., 2009; 
Janzon and Hedblad, 2009). Among those nine studies 
showing positive association, four studies reported a 
significant association among a subset of study partici-
pants (Bolinder et al., 1992; Gupta et al., 2005; Hergens 
et al., 2007; Nasir et al., 2010). One Swedish study 
(Hergens et al., 2007) reported a significant positive 
association between SLT use and fatal CHD, but did not 
find an association for non-fatal CHD. The Indian study 
(Gupta et al., 2005) reported a significant positive asso-
ciation between SLT use and fatal CHD among women 
(OR 1.25, 95% CI 1.05 to 1.49), but did not find an 
association among men (OR 0.94, 95% CI 0.83 to 1.06). 
Similarly, the US study reported a significant positive 
association between SLT use and fatal CHD among 
women (OR 1.25, 95% CI 1.05 to 1.49), but did not find 
an association among men (Nasir et al., 2010). The 
remaining study reported a significant association 
between SLT use  and non-fatal CHD  among  older  men 
  
 
 
(56 to 65 years), but did not find a significant association 
among younger men (46 to 55 years) (Bolinder et al., 
1992). Three studies used SLT products from South Asia 
and reported a significant positive association between 
SLT use and CHD (Gupta et al., 2005; Teo et al., 2006; 
Rahman and Zaman, 2008). 
 
 
Analysis of the Western studies 
 
Table 1 shows the analysis of the studies conducted in 
Western settings. Three out of eleven studies conducted 
in Sweden reported a significant positive association 
between SLT use and CHD (Bolinder et al., 1992, 1994; 
Hergens et al., 2007). One cross-sectional study based 
on the Swedish construction worker study (Bolinder et al., 
1992) reported a significant positive association between 
SLT use and non-fatal CVD in general. However, the 
study reporting the cohort analyses of that research 
(Bolinder et al., 1994) showed a significant positive 
association between SLT use and fatal CHD. The result 
did not change when further follow-up was reported by 
Hergens et al. (2007) with that cohort.  
Four Swedish cohort studies failed to find a statistically 
significant association between SLT use and CHD 
(Johansson et al., 2005; Haglund et al., 2007; Hansson et 
al., 2009; Janzon and Hedblad, 2009). One study did not 
also find any association with frequency and duration of 
SLT use and CHD (Hansson et al., 2009). Another four 
Swedish case-control studies did not find any statistically 
significant association between SLT use and CHD 
(Huhtasaari et al., 1992, 1999; Hergens et al., 2005; 
Wennberg et al., 2007). Subgroup analyses based on 
age in one study (Huhtasaari et al., 1992) were not 
contributory, although this study did not consider the 
known risk factors for CHD as potential confounders 
during analyses. One study (Huhtasaari et al., 1992) also 
examined whether there was a dose-response 
relationship between SLT use and CHD, but none was 
detected. All of these Swedish studies included both fatal 
and non-fatal CHD cases (Table 1) 
Among the four US studies, three studies reported a 
significant positive association between SLT use and 
CHD (Henley et al., 2005; Nasir et al., 2010; Yatsuya and 
Folsom, 2010). Although the US Cancer Prevention 
Study (Henley et al., 2005) found a significant association 
between SLT use and fatal CHD, frequency and duration 
of SLT use were not associated with CHD. In addition, 
the study population included only men. The other two 
studies did not report results for CHD or stroke separately 
(Nasir et al., 2010; Yatsuya and Folsom, 2010). One of 
them (Nasir et al., 2010) reported a significant 
association among women only. The only US study 
(Accortt et al., 2002) that did not find any significant 
association between SLT use and fatal CHD, reported 
similar results when data were analysed according to 
gender (Table 1). 
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In summary, the majority of the Swedish studies did not 
find any significant positive association between SLT use 
and CHD. Results from all of these Swedish studies 
represent men only and were based on SLT products 
used in Sweden. On the other hand, the majority of the 
US studies showed a significant positive association 
between SLT use and CHD. Results from all of these US 
studies were based on SLT products used in the USA. 
 
 
Analysis of the South Asian studies 
 
Table 2 shows the analysis of the studies conducted in 
South Asian settings. The Indian cohort study (Gupta et 
al., 2005) reported a significant association for fatal CHD 
among women only, not among men. Although the study 
reported the association between use of different Indian 
SLT products and CHD mortality along with other 
tobacco-related mortality, the authors acknowledged 
limitations in ascertaining the accurate causes of deaths 
for all participants (Gupta et al., 2005). In addition, there 
was no separate report for the association between fatal 
CHD and specific SLT product, which is particularly 
important as SLT products included betel-quid in that 
study (Gupta et al., 2005).  
On the other hand, although the Bangladeshi study 
(Rahman and Zaman, 2008) included betel-quid within 
SLT products, the study reported each type of SLT 
product separately. Dried tobacco leaf chewing was 
significantly associated with CHD (OR 2.2, 95% CI 1.1 to 
4.5). Similar to the Indian study, the study reported a 
statistically significant association between SLT use and 
CHD among women only (OR 4.5, 95% CI 1.2 to 16.7); 
the confidence interval was wide due to small number of 
participants (n=83) (Rahman and Zaman, 2008). In 
addition, that study was limited by having a small sample 
size (n=207) posing the risk of reduced power of the 
study, and recruiting controls from within a hospital 
setting (Rahman and Zaman, 2008). However, unlike 
other studies, this study included younger population (20 
to 49 years) as the study participants. 
 
 
Analysis of the global study 
 
The global INTERHEART study (Teo et al., 2006) 
reported a significant positive association between 
chewing tobacco and CHD. However, the study did not 
report different SLT products separately for each 
participant country. Furthermore, betel was included in 
addition to chewing tobacco within South Asian SLT 
products (Teo et al., 2006). It was not clear from the 
study whether the significant positive association 
obtained was due to chewing tobacco alone or betel 
chewing alone or both in South Asia (Table 2). 
This is particularly important for clarification in future 
studies because some studies have reported a significant  
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Table 1. Summary of the Western studies exploring the association between coronary heart disease (CHD) and smokeless tobacco (SLT) use. 
 
Source 
Study 
location 
(country) 
Types of study 
Recruitment 
and Follow-
up year 
Sample 
size 
Gender 
Age 
(yrs) at 
baseline 
Types of 
SLT use as 
exposure 
Types of CHD as 
outcome (only 
CHD data were 
considered) 
Results presented 
in this table, based 
on the comparison 
groups 
Key findings regarding 
association between SLT use 
and CHD 
Comments 
Positive association between SLT use and CHD 
Bolinder 
et al. 
(1992) 
Sweden Cross-sectional 1971-74 97586 Men 16-65 
SLT (types 
of SLT not 
defined) 
Non-fatal CVD 
Current SLT users 
vs. never tobacco 
users, (a) 
Age 46-55yrs: OR = 1.6 (95%CI 
0.7-3.5); Age 56-65yrs: OR = 1.5 
(95%CI 1.1-1.9) 
Results for men only, no 
separate reports for CHD 
or stroke, possibility of 
healthy worker effects on 
the association 
 
Bolinder 
et al. 
(1994) 
Sweden Cohort 
1971-74, 
1974-85 
84781 Men 16-65 
SLT (types 
of SLT not 
defined) 
Fatal CHD 
Current SLT users 
vs. never tobacco 
users, (b) 
Age 35-54yrs: RR = 2.0 (95%CI 
1.4-2.9); Age 55-65yrs: RR = 1.2 
(95%CI 1.0-1.5) 
Results for men only, 
SLT use data old 
 
Hergens 
et al. 
(2007) 
Sweden Cohort 
1978-93, 
1978-2004 
118395 Men 16-65 Snuff 
Fatal and non-fatal 
CHD  
Current snuff users 
(never smoked) vs. 
never tobacco 
users, (c) 
Non-fatal CHD: RR = 0.94 (95%CI 
0.83-1.06); Fatal CHD: RR = 1.32 
(95%CI 1.08-1.61); Heavy snuff 
use (≥50gm/day) and fatal CHD 
among 55-65 years: RR = 2.46 
(95% CI 1.09-5.55) 
Results for men only 
 
Henley et 
al. (2005) 
USA Cohort 
1959, 1959-
72 
77407 
Men ≥30 
SLT 
(Chewing 
tobacco, 
snuff) 
Fatal CHD 
Current SLT users 
vs. never tobacco 
users, (d) 
HR = 1.12 (95%CI 1.03-1.21) 
Results for men only, 
SLT use data collected 
at baseline only 
(CPS-I 
study) 
   
1982, 1982-
2000 
113970 HR = 1.26 (95%CI 1.08-1.47);  
Frequency and duration of SLT use 
were not associated with CHD 
(CPS-II 
study) 
            
Yatsuya 
et al. 
(2010) 
USA Cohort 
1987-89, 
1987-2008 
14498 Both 45-64 
SLT (types 
of SLT not 
defined) 
Fatal and non-fatal 
CVD 
Current SLT users 
(never smoked) vs. 
never tobacco 
users, (e) 
HR = 1.31 (95% CI 1.06-1.61) 
No separate reports for 
CHD or stroke 
            
Nasir et 
al. (2010) 
USA 
Cross-sectional 
(Surveillance 
data analyses) 
1999-2001 10332 Both 18-70+ 
SLT (types 
of SLT not 
defined) 
Non-fatal CVD 
Current SLT users 
vs. never tobacco 
users, (f) 
Overall: OR = 1.14 (95% CI 0.55-
2.39), Men: OR = 1.11 (95% CI 
0.87-1.40), Women: OR = 1.72 
(95% CI 1.12-2.65) 
No separate reports for 
CHD or stroke 
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Table 1. Contd. 
 
No positive association between SLT use and CHD 
Johansson 
et al. (2005) 
Sweden Cohort 
1988-89, 
1988-2000 
3120 Men 30-74 Snuff Fatal and non-fatal CHD 
Current snuff 
users (never 
smoked) vs. non-
current snuff 
users, (g) 
HR = 1.41 (0.61-3.28) 
Results for men only, SLT use 
data collected at baseline only 
 
Haglund et 
al. (2007) 
Sweden Cohort 
1988-89, 
1988-2003 
5002 Men 16-74 Snuff Fatal and non-fatal CHD 
Current snuff 
users vs. never 
tobacco users, (h) 
Non-fatal CHD: IRR = 0.77 (95%CI 
0.51-1.15); Fatal CHD: MRR = 1.15 
(95%CI 0.54-2.41) 
Results for men only 
 
Hansson et 
al. (2009) 
Sweden Cohort 
1998-2002, 
1998-2005 
16642 Men 40-72 Snus Fatal and non-fatal CHD 
Current snus 
users (never 
smoked) vs. 
never tobacco 
users, (i) 
RR = 0.85 (95%CI 0.51-1.41); 
Frequency and duration of snus use 
were not associated with CHD 
Results for twin men only 
 
Janzon et al. 
(2009) 
Sweden Cohort 
1991-96, 
1991-2004 
27227 Men 45-73 Snuff Fatal and non-fatal CHD  
Current snuff 
users (never 
smoked) vs. 
never tobacco 
users, (j) 
RR = 0.75 (95%CI 0.3-1.8) Results for men only 
            
Huhtasaari 
et al. (1992) 
Sweden 
Case-
control  
1989-91 
1174 (585 
cases & 589 
controls) 
Men 35-64 Snuff 
Fatal & non-fatal CHD. Cases 
were selected from hospital 
records and death registers; 
controls were selected from 
population registers 
Current snuff 
users vs. never 
tobacco users, (k) 
All age: OR = 0.89 (95%CI 0.62-
1.29); Age 35-54yrs: OR = 0.96 
(95%CI 0.56-1.67); Age 55-64yrs: 
OR = 1.24 (95%CI 0.67-2.30); No 
dose response relationship 
Results for men only, known 
potential confounders for CHD 
were not considered, never 
tobacco users included former 
smoker/snuffers as well as 
occasional smokers/snuffers 
during analysis 
            
Huhtasaari 
et al. (1999) 
Sweden 
Case-
control  
1991-93 
1374 (687 
cases & 687 
matched 
controls) 
Men 25-64 Snuff 
Fatal & non-fatal CHD. Cases 
were selected from hospital 
records and death registers; 
controls were selected from 
population registers 
Current snuff 
users vs. never 
tobacco users, (l) 
Fatal CHD: OR = 1.50 (95%CI 
0.45-5.03); Both fatal and non-fatal 
CHD: OR = 0.58 (95%CI 0.35-0.94) 
Results for men only 
            
Hergens et 
al. (2005) 
Sweden 
Case-
control  
1992-94 
3242 (1432 
cases & 1810 
matched 
controls) 
Men 45-70 Snuff 
Fatal and non-fatal CHD. Cases 
were selected from hospitals 
and mortality register, controls 
were selected from communities 
Current snuff 
users (never 
smoked) vs. 
never tobacco 
users, (m) 
Fatal CHD: OR = 1.7 (95%CI 0.48-
5.5); Non-fatal CHD: OR = 0.59 
(95%CI 0.25-1.4); Both fatal and 
non-fatal CHD: OR = 0.73 (95%CI 
0.35-1.5)  
Results for men only 
 
600          J. Public Health Epidemiol. 
 
 
 
Table 1. Contd. 
 
Wennberg 
et al. (2007) 
Sweden 
Case-
control  
1985-
89 
2323 (525 
cases & 1798 
matched 
controls) 
Men 
30-
60 
Snuff 
Fatal and non-fatal CHD, 
Cases & controls selected 
both from hospitals and 
communities 
Current snuff 
users (Never 
smoked) vs. never 
tobacco users, (n) 
Fatal CHD: OR  = 1.12 (95% 
CI 0.38-3.29); Non-fatal 
CHD: Both fatal and non-
fatal CHD: OR = 0.82 
(95%CI 0.46-1.43) 
Results for men only, controls selected from 
hospital settings having the possibility of 
under-estimation of results using hospital 
controls, no separate reports for hospital 
controls or community controls 
 
Accortt et al. 
(2002) 
USA Cohort 
1971-
75, 
1971-
92 
12451 Both 
45-
75 
SLT (types 
of SLT not 
defined) 
Fatal CHD 
Ever SLT users 
(never smoked) 
vs. never tobacco 
users, (o) 
Men: HR = 0.6 (95%CI 0.3-
1.2); Women: HR = 1.4 
(95%CI 0.8-2.2) 
Never tobacco users included other smokers 
(pipe/cigar) 
 
CVD = cardiovascular diseases, RR = risk ratio, HR = hazard ratio, IRR = incidence rate ratio, MRR = mortality risk ratio, 95%CI = 95% confidence intervals. a) Matching not relevant. Adjusted for: Age, 
gender, race, body mass index, smoking; b) Adjusted for: Age, residential areas, body mass index, blood pressure, diabetes, history of heart symptoms or blood pressure medication, smoking; c) Adjusted for: 
Age, body mass index, residence; d) Adjusted for: Age, race, education, alcohol use, exercise, aspirin use, body mass index, vegetables and fruits intake, dietary fat consumption, occupation; e) Adjusted for: 
Age, gender, race, education, total annual household income, usual alcohol consumption, sports index score, cigarette smoking status, cigarette-years of smoking, pipe use, cigar use, second-hand smoke 
exposure, systolic blood pressure, use of antihypertensive medication, diabetes, waist circumference, total and high-density lipoprotein, cholesterol, triglycerides; f) Adjusted for: Age, gender, race, body mass 
index, smoking; g) Adjusted for: Age, blood pressure, body mass index, diabetes, physical activities; h) Adjusted for: Age, socioeconomic status, residence, self-reported health, number of longstanding 
illness, physical activity; i) Adjusted for: Age, smoking, diabetes, hypertension, serum cholesterol level; j) Adjusted for: Age, body mass index, smoking, diabetes, hypertension, physical activity, marital status, 
occupation; k) Not matched. Adjusted for: Age, education; l) Matched for: Age, residential areas. Adjusted for: Age, residence, smoking, hypertension, diabetes, high cholesterol, education, marriage, family 
history of cardiac death; m) Matched for: Age, hospital catchment areas. Adjusted for: Age, hospital catchment areas, diabetes, hyperlipidemia, hypertension, overweight, physical activity, job strain; n) 
Matched for: Age, gender, date of health survey and geographical region. Adjusted for: Serum cholesterol level, body mass index, physical activity, education; o) Adjusted for: Age, race, poverty index ratio, 
alcohol use, physical activities, fruits and vegetables intake, systolic blood pressure, serum cholesterol level, body mass index. 
 
 
Table 2. Summary of the studies using South Asian smokeless tobacco (SLT) products to explore the association between coronary heart disease (CHD) and smokeless tobacco (SLT) use. 
 
Source 
Study 
location 
(country) 
Types 
of 
study 
Recruitment 
and Follow-
up year 
Sample size Gender 
Age (yrs) 
at 
baseline 
Types of SLT 
use as 
exposure 
Types of CHD as outcome 
(only CHD data were 
considered) 
Results presented 
in this table, 
based on the 
comparison 
groups 
Key findings 
regarding 
association 
between SLT use 
and CHD 
Comments 
Gupta et al. 
(2005) 
India Cohort 1992-94, 
1992-99 
99570 Both ≥35 Mishri, other 
SLT products 
(tobacco plus 
lime) 
Fatal CHD Current SLT users 
vs. never tobacco 
users, (a) 
Men: RR = 0.89 
(95%CI 0.75-1.05); 
Women: RR = 1.25 
(95%CI 1.05-1.49) 
Causes of deaths had 
limitations in classifying, did 
not report the association 
separately for each SLT 
 
Rahman 
and Zaman, 
(2008) 
Banglade
sh 
Case-
control 
2006-07 207 (69 cases 
& 138 controls) 
Both 20-49 Dried tobacco 
leaf 
Non-fatal CHD. Cases & 
controls both were selected 
from hospitals, (b) 
Ever dried tobacco 
leaf users vs. never 
tobacco users 
OR = 2.2 (95%CI 
1.1-4.5). 
Small sample size, hospital-
based study 
            
Teo et al. 
(2006) 
Global Case-
control 
1999-2003 26568 (12133 
cases & 14435 
matched 
controls) 
Both 44-75 SLT (from 
different 52 
countries) 
Non-fatal CHD, Cases were 
selected from hospitals; 
controls were selected both 
from hospitals and 
communities, (c) 
Ever use of SLT 
(never smoked) vs. 
never tobacco 
users 
OR = 2.23 (95% CI 
1.41-3.52) 
No reports for specific SLT 
product of any country, no 
separate reports for 
hospital controls or 
community controls 
 
OR = odds ratio, 95%CI = 95% confidence intervals; a) Not matched. Adjusted for: Age, education; b) Not matched. Adjusted for: Age, gender, hypertension; c) Matched for: Age, gender (but 14% cases 
and 5% controls were not matched perfectly, therefore, unmatched analysis was done). Adjusted for: Age, gender, geographic region, obesity, hypertension, diabetes, apolipoprotein B/apolipoprotein A 
ratio, diet, physical activity, alcohol use. 
  
 
 
positive association between betel chewing alone and 
CHD (Guh et al., 2007; Lin et al., 2008). Although betel-
quid does not contain tobacco, the association was 
thought to be due to the presence of substances in betel-
quid which have both sympathetic and parasympathetic 
activities (Guh et al., 2007; Lin et al., 2008). 
 
 
Quality level of the selected studies 
 
We used the Cochrane GRADE approach to rate the 
quality of the included studies (Higgins and Green, 2011). 
Grading was undertaken by “Muhammad Aziz Rahman”. 
The GRADE approach has perhaps more relevance for 
systematic reviews of clinical studies and because of this 
all  observational  studies  have  a  default rating of ‘low’. 
However, upgrading and downgrading can occur by 
considering the following: design and implementation, 
consistency of results, directness of evidence, precision 
or results, probability of publication bias, magnitude of 
effect, presence of confounders, and dose response 
gradient (Higgins and Green, 2011). Three of the studies 
in this review (Teo et al., 2006; Hergens et al., 2007; 
Hansson et al., 2009) could be upgraded to ‘moderate’, 
whilst no other studies in the review required 
downgrading. 
 
 
DISCUSSION 
 
The  systematic  review  showed  that  in  general,there 
was no association  between  SLT  use  and CHD in 
Swedish studies, but the US and South Asian studies 
have shown an association. It is plausible that these 
differences reflect differences in the content of SLT 
products across countries. Alternatively it could be due 
to differences in the pattern of SLT usage between 
countries, with more pervasive and regular use 
common in South Asian countries. In addition, SLT 
products are commonly consumed with betel-quid in 
South Asian countries and the positive association in 
South Asian studies could be due to the fact that betel 
chewing is independently associated with CHD (Guh et 
al., 2007; Lin et al., 2008). The results also differed 
according to age and gender in some studies as detailed 
in the foregoing. 
Results regarding the association between SLT use 
and CHD differed by age groups of the study participants. 
While the Swedish cross-sectional study did not find a 
significant association between SLT use and CHD among 
young construction workers of 46 to 55 years (Bolinder et 
al., 1992), the Swedish cohort study reported a significant 
association among young as well as older people 
(Bolinder et al., 1994). However, as the participants of 
those studies were recruited from a volunteer health 
check-up group, the possibility of healthy worker effects 
(Shah, 2009)   on   the   non-association   in   the   cross- 
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sectional study (Bolinder et al., 1992) cannot be ruled 
out. In addition, another Swedish case-control study did 
not report any significant association across different age 
groups (Huhtasaari et al., 1992). Although age was 
considered for adjustment during calculation in those 
studies, there remains uncertainty regarding the effects of 
age on the association of SLT use and CHD. On the 
other hand, the cohort study with Swedish construction 
workers collected SLT use data at baseline (Bolinder et 
al., 1994). SLT usage patterns as well as SLT con-
stituents might have been changed within the 12-years 
follow-up period, which was not considered in that study. 
The subsequent cohort study (Hergens et al., 2007) 
utilizing data from the Swedish construction worker 
cohort considered this issue and reported comprehensive 
data on SLT use. 
SLT usage pattern differs by gender and by country. 
While results of all Swedish studies represent men only, 
both genders were considered in three US studies 
(Accortt et al., 2002; Nasir et al., 2010; Yatsuya and 
Folsom, 2010). Two of them (Accortt et al., 2002; Nasir et 
al., 2010) reported an increased risk of CHD with SLT 
use among women compared to men. Similarly, the 
Indian cohort study (Gupta et al., 2005) and the 
Bangladeshi case-control study (Rahman and Zaman, 
2008) reported a significant positive association among 
women only. Although prevalence of SLT use is similar 
among women and men in South Asia (Gupta and Ray, 
2003; World Health Organization-Bangladesh, 2009), 
frequency, amount and duration of SLT use may be 
different between men and women, which were not consi-
dered in either study. Therefore, it is important to explore 
this gender variation in future studies of SLT use and 
CHD.  
The forms of SLT products used in South Asia differ 
from the Western SLT products in constituents, nicotine 
concentration, manufacturing and storage (US National 
Cancer Institute, 2002; McKee et al., 2007). Therefore, it 
is presumed that those Western studies would not be 
generalizable to the South Asian settings. Studies using 
South Asian SLT products exclusively are very limited 
and showed a significant association between SLT use 
and CHD thus far (Gupta et al., 2005; Teo et al., 2006; 
Rahman and Zaman, 2008). But SLT products are also 
not same across all South Asian countries (Stanfill et al., 
2011), results of the studies might be different due to this 
chemical diversity of SLT products. Therefore, it would be 
interesting to have further studies in South Asia to 
explore whether the association between SLT use and 
CHD vary by different types of SLT products. 
Inconsistent results can also be explained by some 
methodological constraints. As for example, some cohort 
studies (Bolinder et al., 1994; Henley et al., 2005; 
Johansson et al., 2005) did not report any information 
whether users switched from SLT use to smoking or not 
during the follow-up period, which is not an uncommon 
practice (Tomar, 2003; Boffetta and  Straif,  2009).  If  the  
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SLT users switched and/or used both tobacco products, 
the positive association in those cohort studies might not 
be true. In a similar way, if the SLT users stopped using 
SLT products during the follow-up period, the non-
association findings of the cohort studies could be due to 
this behavior change. On the other hand, one case-
control study (Wennberg et al., 2007), which did not find 
a significant positive association between SLT use and 
CHD, included partial controls from hospital settings. 
Whilst hospital controls and community controls differ in a 
number of ways such as distribution of exposure 
variables and confounders, recall history, non-response, 
the ORs reported in that study is likely to be under-
estimated due to these issues although there was no 
separate report for hospital controls or community 
controls (Wennberg et al., 2007). Another case-control 
study did not consider the potential confounders for CHD 
during reporting the non-association between SLT use 
and CHD (Huhtasaari et al., 1992). The Indian cohort 
study may have been affected by the difficulty in a 
developing country of having an incomplete death 
register; the outcome in this study was fatal-CHD and 
there may have been inconsistencies in the classification 
of the cause of death (Gupta et al., 2005). Finally, 
presence of unmeasured confounding effects on either 
cohort or case-control studies to explore the association 
between SLT use and CHD cannot be ruled out, such as 
socioeconomic status (SES). Although there is an inverse 
relationship between SES and risk of CHD across 
different ethnic groups (Kraus et al., 1980); SLT users are 
generally from lower SES in South Asian countries 
(Gupta et al., 2003), the opposite may be true for some 
Western countries. SES is an independent risk factor for 
CHD and may be difficult to adequately adjust for even 
with multivariable analyses. 
 
 
Conclusion 
 
This systematic literature review summarized the existing 
evidence regarding the association between SLT use and 
CHD, both in Western and South Asian settings. 
Considering the variable constituents of SLT products 
and different patterns of SLT use between Western and 
South Asian settings, results from Western countries 
cannot be easily applied to South Asian countries.  
Further evidence is required from South Asia regarding 
the association between SLT use and CHD, specifically 
focusing on gender variation and different types of SLT 
products. Studies also need to focus on methodological 
rigour and on populations who have been using SLT 
products as a socio-cultural tradition for hundreds of 
years.  
 
 
LIMITATIONS 
 
Limitations of this review include the possibility of 
excluding relevant studies in this review, as could happen  
 
 
 
 
to any systematic review (Critchley and Unal, 2004). But 
it is unlikely that we missed any important study as the 
search strategy was comprehensive and was conducted 
by an expert in this field. We did not undertake a meta-
analysis, because different methodologies were 
employed by studies and different types of SLT products 
were measured. Meta-analyses have been performed 
earlier with Western studies only (Boffetta and Straif, 
2009) and Asian studies only (Zhang et al., 2010). Our 
objective was to summarise the currently available 
evidence, consider plausible reasons for the different 
findings and through this process, explore the rationale 
for conducting further studies particularly in South Asia. 
We did not seek to make a definitive conclusion at this 
stage about the association between SLT use and CHD. 
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